Pearson χ2 comparison of acute leukemia clinical trial enrollment fractions according to race-ethnicity
| Statistic . | NH-White . | NH-Black . | NH-NA/AN . | NH-Asian . | Hispanic . |
|---|---|---|---|---|---|
| AML | |||||
| Proportion of trial enrollment, % | 79.7 | 7.3 | 0.3 | 3.6 | 9 |
| Enrollment fraction, % | 3.5 | 2.4 | 1.8 | 2.6 | 2.9 |
| OR of enrollment | Ref | 0.68 | 0.31 | 0.75 | 0.83 |
| OR 95% CI | – | 0.61, 0.75 | 0.31, 0.82 | 0.65, 0.86 | 0.76, 0.91 |
| P | – | <.001 | .005 | <.001 | <.001 |
| ALL | |||||
| Proportion of trial enrollment, % | 65.4 | 7.7 | 0.3 | 4.1 | 22.5 |
| Enrollment fraction, % | 3.6 | 2.7 | 1 | 2.4 | 2.3 |
| OR of enrollment | Ref | 0.74 | 0.27 | 0.67 | 0.64 |
| OR 95% CI | – | 0.63, 0.87 | 0.12, 0.61 | 0.54, 0.83 | 0.57, 0.71 |
| P | – | <.001 | .001 | <.001 | <.001 |
| Statistic . | NH-White . | NH-Black . | NH-NA/AN . | NH-Asian . | Hispanic . |
|---|---|---|---|---|---|
| AML | |||||
| Proportion of trial enrollment, % | 79.7 | 7.3 | 0.3 | 3.6 | 9 |
| Enrollment fraction, % | 3.5 | 2.4 | 1.8 | 2.6 | 2.9 |
| OR of enrollment | Ref | 0.68 | 0.31 | 0.75 | 0.83 |
| OR 95% CI | – | 0.61, 0.75 | 0.31, 0.82 | 0.65, 0.86 | 0.76, 0.91 |
| P | – | <.001 | .005 | <.001 | <.001 |
| ALL | |||||
| Proportion of trial enrollment, % | 65.4 | 7.7 | 0.3 | 4.1 | 22.5 |
| Enrollment fraction, % | 3.6 | 2.7 | 1 | 2.4 | 2.3 |
| OR of enrollment | Ref | 0.74 | 0.27 | 0.67 | 0.64 |
| OR 95% CI | – | 0.63, 0.87 | 0.12, 0.61 | 0.54, 0.83 | 0.57, 0.71 |
| P | – | <.001 | .001 | <.001 | <.001 |
ClinicalTrials.gov trials from 2002 to 2017 reporting race and ethnicity data. AML, n = 6554; ALL, n = 4149. Significant results are listed in bold. OR, odds ratio; CI, confidence interval.